Cannabis Science Inc a development stage company, engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products.

Cannabis Science, Inc. (otcqb:CBIS) announced in late April the initiation of preclinical development characterization of CS-TATI-I following the execution of contractual retention of vendor labs located in the Amsterdam Life Science Cluster.

AMSTERDAM, April 26, 2013 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS) announced today the initiation of preclinical development characterization of CS-TATI-I following the execution of contractual retention of vendor labs located in the ...

Cannabis Science Inc. is researching on cannabis-based medicines and products. The company is also working on research and development in medical marijuana.

Cannabis Science, Inc. (CBIS) announced the initiation of preclinical development characterization of CS-TATI-I following the execution of contractual retention of vendor labs located in the Amsterdam Life Science Cluster.

Cannabis Science Inc a development stage company, engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products.

Cannabis Science, Inc. is researching on cannabis-based medicines and products. The company is also working on research and development in medical marijuana.

Cannabis Science Inc (OTCMKTS:CBIS) decreased -2.02% and closed at $0.0485 on a traded volume of 1.50 million shares, in comparison to 3.66 million shares of average trading volume.

So was Growlife Inc. (OTC:PHOT). So was Cannabis Science Inc. (PINK:CBIS). In fact, CBIS, PHOT, and MJNA all started to perk up in October of last year when marijuana (recreational as well as medical usage) was slated to appear on ballots in several ...

The current traded volume of the company stands at 2.3 million shares which is modestly higher as compared to its average shares of 5.59 million.